CAR T Cell Therapy–Related Cardiovascular Outcomes and Management

CAR T Cell Therapy–Related Cardiovascular Outcomes and Management

CD19-specific chimeric antigen receptor (CAR) T cell therapies have shown remarkable early success in highly refractory and relapsing hematological malignancies. However, this potent therapy is accompanied by significant toxicity. Cytokine release syndrome and neurotoxicity are the most widely repor...

Full description

Bibliographic Details
Main Authors: Arjun K. Ghosh, MBBS, MSc, PhD, Daniel H. Chen, BMed, Avirup Guha, MD, Strachan Mackenzie, MBBS, BSc, J. Malcolm Walker, MD, Claire Roddie, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-03-01
Series:JACC. CardioOncology
Subjects:
cardiomyopathy
cytokine release syndrome
immunotherapy
leukemia
lymphoma
Online Access:http://www.sciencedirect.com/science/article/pii/S2666087320300193

Internet

http://www.sciencedirect.com/science/article/pii/S2666087320300193

Similar Items